Pulmonary hypertension associated with left heart disease

被引:2
作者
Wissmueller, Max [1 ]
Dohr, Johannes [1 ]
Adler, Joana [1 ]
Ochs, Laurin [1 ]
Tichelbaecker, Tobias [1 ]
Hohmann, Christopher [1 ]
Baldus, Stephan [1 ]
Rosenkranz, Stephan [1 ]
机构
[1] Univ Cologne, Clin Int Med 3, Fac Med, Cologne Cardiovasc Res Ctr CCRC,Heart Ctr,Univ Hos, Kerpener Str 62, D-50937 Cologne, Germany
关键词
Cardiomyopathy; Heart failure; Valvular heart disease; Pulmonary artery pressure; Hemodynamics; PRESERVED EJECTION FRACTION; GUANYLATE-CYCLASE STIMULATOR; FAILURE PATIENTS; DOUBLE-BLIND; OUTCOMES; THERAPY; DYSFUNCTION; SILDENAFIL; VERICIGUAT; MORTALITY;
D O I
10.1007/s00059-023-05189-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary hypertension (PH) is a common condition in patients with left heart disease (LHD) that is highly relevant for morbidity and mortality. While post-capillary in nature, the pathophysiology of PH in patients with LHD (heart failure/cardiomyopathy, valvular heart disease; other: congenital/acquired) is complex, and decisions about management strategies are challenging. Recently, the updated European Society of Cardiology/European Respiratory Society guidelines on the diagnosis and treatment of PH revisited hemodynamic definitions and the sub-classification of post-capillary PH, and provided numerous new recommendations on the diagnosis and management of PH associated with various types of LHD. Here, we review several novel aspects that focus on: (a) updated hemodynamic definitions, including the distinction between isolated post-capillary PH (IpcPH) and combined post- and pre-capillary PH (CpcPH); (b) the pathogenesis of PH-LHD, considering various components contributing to PH, such as pulmonary congestion, vasoconstriction, and vascular remodeling; (c) the prognostic relevance of PH and hemodynamic markers; (d) the diagnostic approach to PH-LHD; (e) management strategies in PH-LHD, distinguishing between targeting the underlying left heart condition, the pulmonary circulation, and/or impaired right ventricular function. In conclusion, precise clinical and hemodynamic characterization and detailed phenotyping are essential for prognostication and the management of patients with PH-LHD.
引用
收藏
页码:266 / 273
页数:8
相关论文
共 53 条
  • [1] Implantable Hemodynamic Monitoring for Heart Failure Patients
    Abraham, William T.
    Perl, Leor
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (03) : 389 - 398
  • [2] Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial
    Abraham, William T.
    Stevenson, Lynne W.
    Bourge, Robert C.
    Lindenfeld, Jo Ann
    Bauman, Jordan G.
    Adamson, Philip B.
    [J]. LANCET, 2016, 387 (10017) : 453 - 461
  • [3] Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: theCardioMEMS EuropeanMonitoringStudy forHeartFailure (MEMS-HF)
    Angermann, Christiane E.
    Assmus, Birgit
    Anker, Stefan D.
    Asselbergs, Folkert W.
    Brachmann, Johannes
    Brett, Marie-Elena
    Brugts, Jasper J.
    Ertl, Georg
    Ginn, Greg
    Hilker, Lutz
    Koehler, Friedrich
    Rosenkranz, Stephan
    Zhou, Qian
    Adamson, Philip B.
    Boehm, Michael
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (10) : 1891 - 1901
  • [4] Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
    Armstrong, Paul W.
    Pieske, Burkert
    Anstrom, Kevin J.
    Ezekowitz, Justin
    Hernandez, Adrian F.
    Butler, Javed
    Lam, Carolyn S. P.
    Ponikowski, Piotr
    Voors, Adriaan A.
    Jia, Gang
    McNulty, Steven E.
    Patel, Mahesh J.
    Roessig, Lothar
    Koglin, Joerg
    O'Connor, Christopher M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) : 1883 - 1893
  • [5] Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the MEMS-HF study
    Assmus, Birgit
    Angermann, Christiane E.
    Alkhlout, Basil
    Asselbergs, Folkert W.
    Schnupp, Steffen
    Brugts, Jasper J.
    Nordbeck, Peter
    Zhou, Qian
    Brett, Marie-Elena
    Ginn, Greg
    Adamson, Philip B.
    Bohm, Michael
    Rosenkranz, Stephan
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (12) : 2320 - 2330
  • [6] Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long-Term Survival
    Bermejo, Javier
    Gonzalez-Mansilla, Ana
    Mombiela, Teresa
    Fernandez, Ana I.
    Martinez-Legazpi, Pablo
    Yotti, Raquel
    Garcia-Orta, Rocio
    Sanchez-Fernandez, Pedro L.
    Castano, Mario
    Segovia-Cubero, Javier
    Escribano-Subias, Pilar
    Alberto San Roman, J.
    Borras, Xavier
    Alonso-Gomez, Angel
    Botas, Javier
    Crespo-Leiro, Maria G.
    Velasco, Sonia
    Bayes-Genis, Antoni
    Lopez, Amador
    Munoz-Aguilera, Roberto
    Jimenez-Navarro, Manuel
    Gonzalez-Juanatey, Jose R.
    Evangelista, Arturo
    Elizaga, Jaime
    Martin-Moreiras, Javier
    Gonzalez-Santos, Jose M.
    Moreno-Escobar, Eduardo
    Fernandez-Aviles, Francisco
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (02): : 1 - 21
  • [7] Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial
    Bermejo, Javier
    Yotti, Raquel
    Garcia-Orta, Rocio
    Sanchez-Fernandez, Pedro L.
    Castano, Mario
    Segovia-Cubero, Javier
    Escribano-Subias, Pilar
    Alberto San Roman, Jose
    Borras, Xavier
    Alonso-Gomez, Angel
    Botas, Javier
    Crespo-Leiro, Maria G.
    Velasco, Sonia
    Bayes-Genis, Antoni
    Lopez, Amador
    Munoz-Aguilera, Roberto
    de Teresa, Eduardo
    Gonzalez-Juanatey, Jose R.
    Evangelista, Arturo
    Mombiela, Teresa
    Gonzalez-Mansilla, Ana
    Elizaga, Jaime
    Martin-Moreiras, Javier
    Gonzalez-Santos, Jose M.
    Moreno-Escobar, Eduardo
    Fernandez-Aviles, Francisco
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 (15) : 1255 - 1264
  • [8] Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction A Phase IIb Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Hemodynamic Study
    Bonderman, Diana
    Ghio, Stefano
    Felix, Stephan B.
    Ghofrani, Hossein-Ardeschir
    Michelakis, Evangelos
    Mitrovic, Veselin
    Oudiz, Ronald J.
    Boateng, Francis
    Scalise, Andrea-Viviana
    Roessig, Lothar
    Semigran, Marc J.
    [J]. CIRCULATION, 2013, 128 (05) : 502 - U95
  • [9] A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)
    Califf, RM
    Adams, KF
    McKenna, WJ
    Gheorghiade, M
    Uretsky, BF
    McNulty, SE
    Darius, H
    Schulman, K
    Zannad, F
    HandbergThurmond, E
    Harrell, FE
    Wheeler, W
    SolerSoler, J
    Swedberg, K
    [J]. AMERICAN HEART JOURNAL, 1997, 134 (01) : 44 - 54
  • [10] Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
    Codina, Pau
    Domingo, Mar
    Barcelo, Elena
    Gastelurrutia, Paloma
    Casquete, Daniel
    Vila, Joan
    Abdul-Jawad Altisent, Omar
    Spitaleri, Giosafat
    Cediel, German
    Santiago-Vacas, Evelyn
    Zamora, Elisabet
    Ruiz-Cueto, Maria
    Santesmases, Javier
    de la Espriella, Rafael
    Pascual-Figal, Domingo A.
    Nunez, Julio
    Lupon, Josep
    Bayes-Genis, Antoni
    [J]. ESC HEART FAILURE, 2022, 9 (04): : 2170 - 2180